Remote Digital Physiologic Data Collection in Cancer: An MSK Registry Protocol

Recruiting now

Conditions studied: Solid Tumor

In brief

The purpose of this study is to develop a secure method of collecting physiologic information from patients with cancer. The researchers will use this information to learn more about how physiologic data may relate to cancer diagnosis and response to treatment, and to identify factors that may lead to higher or lower risk of cancer.

Key facts

Study ID

NCT05390827

Run by

Memorial Sloan Kettering Cancer Center

People needed

3692

Starts

2022-05-19

Expected to finish

2027-07-01

Last updated by the study team

2026-07-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Project 1: HealthKit
• Individuals who meet at least one of the following criteria:
• Diagnosis of new onset early-stage (I-III), low-grade (I-II), or locally advanced solid tumor
• Historical diagnosis of primary invasive solid tumor
• Diagnosis of metastatic (stage IV) or high-grade (III-IV) disease
• Enrolled onto an investigational trial in the EDD Service
• Seen in the MSK UCC from 2021 and onwards
• Completion of Survivorship Patient Self-Assessment
• Adult without a history of cancer <50 years of age
• Adult without a history of cancer ≥ 50 years of age
• ≥18 years old
• Own an Apple iPhone or Android with valid operating software
• Self-reported "very well" comprehension of written and verbal English language
• Willing and able to provide informed consent and HIPAA authorization for the release of personal health information
• Project 2: DigIT-Ex
• Individuals who meet one of the following criteria:
• Patients at MSK who are:
• Scheduled to undergo any type of BMT (Cohort 1)
• Diagnosed with new onset AML and scheduled to initiate antineoplastic therapy (Cohort 2)
• Scheduled to undergo any surgery for prostate cancer (Cohort 3)
• Scheduled to undergo any lung cancer surgery (Cohort 4)
• Scheduled to undergo TNT for locally advanced rectal cancer (Cohort 5)
• Scheduled to initiate androgen deprivation therapy for at least 12 months and has one of the following prostate cancer diagnoses (Cohort 6):
• High risk/very high localized, locally advanced,
• Biochemically recurrent prostate cancer

You may not qualify if…

• Project 1: HealthKit
• Unable or unwilling to successfully export and /or share physiological data
• Project 2: DigIT-Ex
• Unable or unwilling to appropriately use digital platforms or devices
• Require a wheelchair for ambulation (Cohort 10)
• Are undergoing stabilization surgery for a primary bone tumor (rather than metastatic disease) (Cohort 10)

Where it is running

• Memorial Sloan Kettering Cancer Center — New York, New York, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.